Patients on benralizumab, dupilumab, or mepolizumab have lower post-vaccination SARS-CoV-2 immunity

In a prospective observational study, patients with asthma or atopic dermatitis treated with benralizumab, dupilumab, or mepolizumab exhibited lower post-vaccination SARS-CoV-2 antibody levels, neutralization activity, and Spike-specific lymphocyte memory responses than subjects not on biologics.

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 154; no. 2; pp. 435 - 446
Main Authors Runnstrom, Martin C., Lamothe, Pedro A., Faliti, Caterina E., Cheedarla, Narayanaiah, Moreno, Alberto, Suthar, Mehul S., Nahata, Rishika, Ravindran, Mayuran, Haddad, Natalie S., Morrison-Porter, Andrea, Quehl, Hannah, Ramonell, Richard P., Woodruff, Matthew, Anam, Fabliha, Zhang, Rebeca, Swenson, Colin, Polito, Carmen, Neveu, Wendy, Patel, Rahulkumar, Smirnova, Natalia, Kim, Caroline, Hentenaar, Ian, Kyu, Shuya, Usman, Sabeena, Ngo, Thuy, Guo, Zhenxing, Wu, Hao, Daiss, John L., Park, Jiwon, Manning, Kelly E, Wali, Bursha, Ellis, Madison L., Sharma, Sunita, Holguin, Fernando, Cheedarla, Suneethamma, Neish, Andrew S., Roback, John D., Sanz, Ignacio, Lee, F. Eun-Hyung
Format Journal Article
LanguageEnglish
Published 13.06.2024
Online AccessGet full text

Cover

More Information
Summary:In a prospective observational study, patients with asthma or atopic dermatitis treated with benralizumab, dupilumab, or mepolizumab exhibited lower post-vaccination SARS-CoV-2 antibody levels, neutralization activity, and Spike-specific lymphocyte memory responses than subjects not on biologics.
Bibliography:MCR and MR screened and recruited the patients.
RP, SU and TN helped with patient enrollment.
RPR, MW, NS, and IS provided scientific input to the experimental design and data interpretation.
CS, CP, WN, SS and FH recruited research subjects from their clinics.
NSH, AMP, HQ, FA and CK performed multiplexed immunoassays for antibody titers.
PAL, CEF, JP performed flow cytometry data analysis.
MCR and PAL wrote the manuscript text.
AM and MSS developed and performed live virus neutralization assays.
MCR, SK, IH and CK processed samples.
These authors contributed equally to this work
NSH and JLD developed and optimized the multiplexed immunoassays.
FEL provided scientific oversight of the entire project.
FEL and MCR conceptualized the study.
NC, ASN, JDR and SC developed and performed pseudovirus neutralization assays.
Author contributions
MCR and PAL created the figures for the manuscript.
MCR, CEF and RN performed flow cytometry experiments.
PAL, MCR, RZ, ZG, NS and HW performed statistical analysis.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2024.03.029